Nan Fung Trinity HK Ltd. Acquires 1,687,310 Shares of Savara Inc. $SVRA

Nan Fung Trinity HK Ltd. increased its holdings in Savara Inc. (NASDAQ:SVRA – Free Report) by 1,088.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,842,350 shares of the company’s stock after acquiring an additional 1,687,310 shares during the quarter. Nan Fung Trinity HK Ltd.’s holdings in Savara were worth $9,507,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. purchased a new stake in Savara in the 2nd quarter valued at $76,966,000. Nantahala Capital Management LLC acquired a new stake in Savara during the 2nd quarter worth $42,977,150. Spruce Street Capital LP purchased a new position in Savara during the 2nd quarter worth $21,267,868. ADAR1 Capital Management LLC purchased a new position in Savara during the 2nd quarter worth $8,645,000. Finally, Algert Global LLC grew its position in Savara by 53.7% during the 2nd quarter. Algert Global LLC now owns 1,329,259 shares of the company’s stock worth $8,188,000 after purchasing an additional 464,645 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Citigroup reissued a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on Savara in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target on the stock. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Finally, HC Wainwright started coverage on Savara in a research note on Thursday. They set a “buy” rating and a $10.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.29.

Check Out Our Latest Research Report on Savara

Savara Price Performance

NASDAQ:SVRA opened at $4.72 on Friday. The firm’s fifty day moving average price is $4.95 and its 200 day moving average price is $5.34. Savara Inc. has a 1-year low of $4.03 and a 1-year high of $7.01. The company has a current ratio of 8.55, a quick ratio of 10.13 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Sell-side analysts anticipate that Savara Inc. will post -0.67 earnings per share for the current fiscal year.

About Savara

(Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

See Also

Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).

Institutional Ownership by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.